Ann: Becoming a substantial holder-IPD.AX, page-8

IMO that's why it's potentially a good shorting stock. IPD is currently valued on forward potential rather than actual sales, and it has a fairly decent market cap of $350MM so the market is expecting sales to build quickly now that it is commercially launched especially with the high rebate. If IPD fail to deliver quickly enough on this front, sentiment may sour and drag the MC down quickly. Also expenditure will likely increase with the new clinical trials in CHF so losses will continue for a while. UBS will either benefit from a rising share price or loan stock out for shorting, either way they win! Let's hope the sales go well and the shorts don't get a look in. IPD does seem to have a fairly tight and large institutional register so hopefully there won't be too many swings.